Identifying breast cancer patients most likely to benefit from trastuzumab

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news